Page 1874 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

66. George D, Erkan D. Antiphospholipid syndrome. Prog 76. Curtis JR, Singh JA. Use of biologics in rheumatoid arthri-
Cardiovasc Dis. September-October 2009;52(2):115-125. tis: current and emerging paradigms of care. Clin Ther. June
67. Westney GE, Harris EN. Catastrophic antiphospholipid 2011;33(6):679-707.
syndrome in the intensive care unit. Crit Care Clin. October 77. Johnson PW, Glennie MJ. Rituximab: mechanisms and applica-
2002;18(4):805-817. tions. Br J Cancer. November 30, 2001;85(11):1619-1623.
68. Asherson RA. The catastrophic antiphospholipid (Asherson’s) 78. Buch MH, Emery P. New therapies in the management of
syndrome. Autoimmun Rev. December 2006;6(2):64-67. rheumatoid arthritis. Curr Opin Rheumatol. May 2011;23(3):
69. Sahn SA, Lakshminarayan S. Tuberculosis after corticosteroid 245-251.
therapy. Br J Dis Chest. July 1976;70(3):195-205. 79. Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of
70. Iseman MD. Tuberculosis prophylaxis during corticosteroid patients with adult Still’s disease to biologic agents: multicenter
therapy. JAMA. July 10, 1987;258(2):263-264. results in Japan. Mod Rheumatol. 2012;22(5):712-719.
71. Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B. 80. Lateef A, Petri M. Biologics in the treatment of systemic lupus
Perioperative glucocorticoid coverage. A reassessment 42 years after erythematosus. Curr Opin Rheumatol. September 2010;22(5):
emergence of a problem. Ann Surg. April 1994;219(4):416-425. 504-509.
72. Meyer NJ, Hall JB. Relative adrenal insufficiency in the ICU: 81. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and
can we at least make the diagnosis? Am J Respir Crit Care Med. safety of belimumab in patients with active systemic lupus
December 15, 2006;174(12):1282-1284. erythematosus: a randomised, placebo-controlled, phase 3 trial.
Lancet. February 26, 2011;377(9767):721-731.
73. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic
acid supplementation on the toxicity of low-dose methotrexate 82. Nguyen TC, Kiss JE, Goldman JR, Carcillo JA. The role of
in patients with rheumatoid arthritis. Arthritis Rheum. January plasmapheresis in critical illness. Crit Care Clin. July 2012;28(3):
1990;33(1):9-18. 453-468, vii.
74. Kazatchkine MD, Kaveri SV. Immunomodulation of autoim- 83. Casian A, Jayne D. Plasma exchange in the treatment of
mune and inflammatory diseases with intravenous immune Wegener’s granulomatosis, microscopic polyangiitis, Churg-
globulin. N Engl J Med. September 6, 2001;345(10):747-755. Strauss syndrome and renal limited vasculitis. Curr Opin
Rheumatol. January 2011;23(1):12-17.
75. NIH consensus conference. Intravenous immunoglobulin.
Prevention and treatment of disease. Jama. December 26, 1990;
264(24):3189-3193.

Section11-O-Ref.indd 3 12/10/2014 8:08:27 PM